CytoSite Bio (CytoSite) announced today that they have signed a collaboration agreement for the clinical development and potential commercialization of CytoSite's investigational Phase 1 ready ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

A Tillamook woman is using her diagnosis of stage three rectal cancer to educate others on the importance of early screening.

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug ...

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.

• In advanced-stage HL, reduction of chemotherapy or radiotherapy after a negative interim PET scan is probably beneficial for overall survival. • Treatment escalation with rituximab after a positive ...

The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...